Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter, Blueprint Initiative, Eidogen-Sertanty, Lester Crawford, Steven Galson, Janet Woodcock, Natalie Dakers, Connie Eaves, Thomas Hudson, Kelvin Ogilvie, Jacques Simard, Ronald Worton


New Products

Beckman Coulter announced last week the addition of new lines of non-human antibodies, cell signaling reagents and multiplex bead assays to the company's existing antibody portfolio. The new products are highlighted in the new Cellular Analysis Catalog which describes over 3,200 products, including 1,800 new animal antibodies and a new menu of MHC tetramers for T-cell research.

The catalog is available free of charge. It can be ordered on line at

The Blueprint Initiative has released Armadillo, a new software tool for mapping linker regions and domain boundaries in proteins. Armadillo predicts domain and linker boundaries using a domain-linker propensity index that was constructed by comparing the amino acid composition of linkers in a non-redundant domain dataset. The index converts the amino acid sequence of a test protein into a numerical profile, providing scientists with a graphical view of domain boundaries, Blueprint said. The system is described in the current issue of the Journal of Molecular Biology [Dumontier et al. J. Mol. Biol. 2005, 350, 1061-1073], and is available at

Eidogen-Sertanty said it has upgraded its Kinase Knowledgebase (KKB) to include more than 390,000 unique kinase molecules and more than 160,000 structure-activity-relationship data points mined from approximately 1,900 journal articles and patents. The company said that the KKB is released quarterly and has a growth rate of more than 50,000 SAR data points and 90,000 unique structures per year.

Movers & Shakers

US Food and Drug Administration Commissioner Lester Crawford has appointed Steven Galson to be director of the FDA's Center for Drug Evaluation and Research, the agency said in a statement this week.

Galson, a rear admiral in the commissioned corps of the US Public Health Service, had most recently served as acting center director, and formerly served as deputy director since he joined the FDA in 2001. Galson holds a BS from Stony Brook University, an MD from the Mt. Sinai School of Medicine and an MPH from the Harvard School of Public Health.

Galson replaces Janet Woodcock as director of the CDER. Woodcock has been named deputy commissioner for operations and chief operating officer at the FDA, Crawford said.

As of this week, Genome Canada's board includes Natalie Dakers, the CEO of British Columbia's Centre for Drug Research and Development; Connie Eaves a professor of medicine at the University of British Columbia; Thomas Hudson, the director of the McGill University and Genome Quebec Innovation Centre and a past assistant-director of the Whitehead Institute/MIT Center for Genome Research; Kelvin Ogilvie, a professor of chemistry at Acadia University in Nova Scotia; Jacques Simard, the director of the Cancer Genomics Laboratory at Centre Hospitalier Universitaire de Québec; and Ronald Worton, the CEO and scientific director for the Ottawa Health Research Institute.


ProteoMonitor will not publish on Aug. 12 and Aug. 19. The next issue of the newsletter will appear on Aug. 26.


The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.